R vs. Phoenix & SAS? [🇷 for BE/BA]

posted by yjlee168 Homepage – Kaohsiung, Taiwan, 2015-04-20 21:36 (3714 d 01:43 ago) – Posting: # 14719
Views: 24,785

Dear Helmut,

❝ What would we need in bear?


Wow! thank you so much. But that's too much. It must be a typo. May I suggest as "what we can do with R?" There are lots of R users/gurus in this Forum.

❝ For the FDA that would be a mixed-effects model as given in the 2001 guidance and the pro­ge­sterone guidance.


I like this.

❝ For the EMA we would need an “all effects fixed” model (Method A of the Q&A).


One stupid question :-D: if EMA needs an "all effects fixed" model, why do we use a mixed model to do analysis? I don't remember lme() right now, but lmer() must have at least a random variable. I tried lmer() last night and was pretty sure about that. Does EMA imply that we should use lm() to analyze replicate crossover dataset?:confused:

FDA – RSABE: Again the progesterone guidance.

❝ EMA – ABEL: The Q&A, Methods A & B. Crippled model to get CVwR...


❝ I would say, that’s the target.


You should try to get funded from EMA or FDA for these projects. These are really great projects, indeed.

All the best,
-- Yung-jin Lee
bear v2.9.2:- created by Hsin-ya Lee & Yung-jin Lee
Kaohsiung, Taiwan https://www.pkpd168.com/bear
Download link (updated) -> here

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,674 registered users;
51 visitors (0 registered, 51 guests [including 13 identified bots]).
Forum time: 23:20 CEST (Europe/Vienna)

Complex, statistically improbable things are by their nature
more difficult to explain than
simple, statistically probable things.    Richard Dawkins

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5